Drug intelligence / Profile preview

PTD2021P

Development stage: Unknown
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

PTD2021P is a mesenchymal stem/stromal cell (MSC) exosome ointment developed for topical application in the treatment of psoriasis. It works through the immunomodulatory properties of MSC exosomes, which can mitigate inflammation by promoting anti-inflammatory cytokines, stimulating Treg polarization, and preventing complement activation. In preclinical studies, topical application of MSC exosomes reduced C5b-9, IL-17, and IL-23 levels in a psoriasis mouse model. The drug is being positioned as an alternative therapeutic option for patients who are refractory to current first-line psoriasis treatments.

Other names: MSC exosome ointmenttopical exosome ointment

Targets

C5b-9 (Membrane attack complex (MAC / C5b-9))

Beyond the preview

Go deeper on PTD2021P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTD2021P.

Explore the full profile